CLL/SLL

Assoc. Prof. Nicole Lamanna | ASH 2017 | DUO Trial: Based on phase III DUO trial, which CLL patients would most benefit from duvelisib therapy?

L:

59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA

Associate Professor Nicole Lamanna
Columbia University Medical Center, New York, US

Interview topic: Based on phase III DUO trial, which CLL patients would most benefit from duvelisib therapy?

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF